The Great Transatlantic Divide: The Case of Experimental Neuropharmacology
Clinical Drug Investigation · 2026-11 · 46 (11) · 1209-1212
DOI: 10.1007/s40261-026-01593-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Drug Investigation, online erschienen am 08.09.2026. Verfasst von Carlo Colosimo. Beteiligte Einrichtung: Department of Neurology, LUM University, "F. Miulli" Regional General Hospital, 70021, Acquaviva delle Fonti, Bari, Italy. colosimo@lum.it. Hauptthemen laut MEDLINE: Drug Approval, Neuropharmacology, Nervous System Diseases. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Despite substantial agreement between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on new drug approval in the past decades, a few new drugs for the treatment of some of the most prevalent and severe neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, as well as much rarer neurogenetic disorders, were handled differently by the two regulatory agencies. The possible reasons for the differing behaviors of the FDA and EMA are several and wide-ranging, and they will be examined in this opinion-based analysis. How patients’ perceptions of the complex approaches to drug approval and commercialization may create disappointment and confusion will also be reappraised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, LUM University, "F. Miulli" Regional General Hospital, 70021, Acquaviva delle Fonti, Bari, Italy. colosimo@lum.it.
Zitieren
APA
Colosimo, C. (2026). The Great Transatlantic Divide: The Case of Experimental Neuropharmacology. Clinical Drug Investigation, 46(11), 1209-1212. https://doi.org/10.1007/s40261-026-01593-5
Vancouver
Colosimo C. The Great Transatlantic Divide: The Case of Experimental Neuropharmacology. Clinical Drug Investigation. 2026;46(11):1209-1212. doi:10.1007/s40261-026-01593-5
BibTeX
@article{Colosimo2026,
author = {Colosimo, Carlo},
title = {The Great Transatlantic Divide: The Case of Experimental Neuropharmacology},
journal = {Clinical Drug Investigation},
year = {2026},
volume = {46},
number = {11},
pages = {1209--1212},
doi = {10.1007/s40261-026-01593-5}
}
EUVIMED